神經痛治療市場－全球產業規模、佔有率、趨勢、機會和預測：按治療方法、適應症、分銷管道、地區和競爭格局分類，2021-2031年

全球神經痛治療市場預計將從 2025 年的 13.4 億美元大幅成長至 2031 年的 22.3 億美元，複合年成長率為 8.86%。

該市場涵蓋多種藥物療法和干涉措施，旨在治療神經病變。神經性疼痛是一種慢性疾病，其特徵是由神經損傷引起的劇烈、刺痛或灼痛。推動此市場成長的主要因素包括：全球老年人口的快速成長（老年人尤其容易患上帶狀皰疹後遺症神經痛等疾病），以及糖尿病等慢性代謝性疾病盛行率的上升（這些疾病常導致周邊神經病變）。

儘管市場成長迅速，但擴張仍面臨許多障礙。這些障礙包括藥物副作用和複雜的診斷程序，這往往導致患者治療依從性低，甚至出現漏診病例。有效醫療服務和市場滲透的主要障礙之一是漏診率高。例如，美國糖尿病協會 (ADIA) 估計，到 2025 年，遠端對稱性多發性神經病變可能影響至少 10% 至 15% 的新診斷 2 型糖尿病患者。這凸顯了大量患者儘管需要早期神經病變治療卻未被確診，從而限制了現有治療方法的市場覆蓋範圍。

市場促進因素

糖尿病及其相關糖尿病神經病變的日益普遍是全球神經疼痛治療市場的主要驅動力。慢性高血糖會系統性地損害周邊神經，導致大量患者患有疼痛性糖尿病神經病變（PDN），需要持續使用止痛藥和抗驚厥藥物治療。不斷成長的患者群體需要開發並持續增加用於治療神經病變疼痛的解決方案。根據國際糖尿病聯盟（IDF）將於2025年12月發布的第11版《糖尿病地圖集》，到2024年，全球將有約5.89億成年人患有糖尿病，其中大多數最終都需要接受神經病變治療，這確保了糖尿病神經病變仍將是推動市場需求的主要臨床適應症。

同時，藥物治療和外科疼痛管理領域的持續進步正在迅速擴大市場範圍。製造商越來越重視非鴉片類藥物和先進神經調控設備的研發，以克服傳統治療方法的限制。這項策略轉變的特點是大量投資和關鍵監管里程碑的達成，旨在提高治療效果和患者安全性，例如波士頓科學公司於2025年10月以約5.33億美元收購Naroo Medical，整合了先進的外周神經刺激技術。此外，下一代系統的監管核准，例如美國FDA於2025年核准Saluda Medical的EVA程式平台用於最佳化脊髓刺激效果，正在加速這些系統的應用。

市場挑戰

診斷的複雜性對全球神經性疼痛治療​​市場的擴張構成了重大挑戰。神經病變疼痛具有主觀性，通常難以透過標準臨床檢查進行識別，尤其是在早期階段。由於這些感覺可能與其他疾病的症狀相似，醫療專業人員往往難以準確定位特定的神經損傷，從而經常導致診斷延遲或漏診。如果患者未能獲得明確診斷，他們可能無法獲得必要的藥物或介入措施，因此可能會錯過接受這些用戶層的治療方法。

高比例的未確診病例直接限制了潛在市場規模。由於缺乏明確診斷，患者無法產生對處方止痛藥或神經刺激設備的需求，導致實際盛行率與治療收入之間存在顯著差距。周邊神經病變基金會估計，到2025年，美國將有約3,000萬人患有某種形式的周邊神經病變，但這些診斷難題意味著相當一部分患者將無法接受治療。這一差距凸顯了由於當前臨床限制而尚未開發的巨大潛在市場價值。

市場趨勢

選擇性電壓依賴性鈉通道阻斷劑的研發代表著藥物干預領域的變革性轉變，使治療方向從廣譜鎮痛藥轉向精準靶向外周疼痛訊號的治療方法。這一趨勢著重於抑制特定離子通道，例如在傷害感受器中高表達且對神經病變疼痛傳遞至關重要的NaV1.8通道，這對於避免鴉片類藥物相關的中樞神經系統副作用至關重要。這項機制的檢驗正在迅速推進，從而建立了一類直接針對神經痛生理根源的新型療法。一個典型的例子是Vertex Pharmaceuticals公司於2025年1月宣布，美國FDA批准了高選擇性NaV1.8疼痛訊號抑制劑suzetrigine上市。這核准20多年來首個用於治療急性疼痛的新型藥物，同時，該藥物用於治療糖尿病周邊神經神經病變的III期臨床試驗也正在進行中。

同時，新一代神經調控設備的進步正在透過引入封閉回路型系統重新定義介入治療的模式。這些閉迴路系統能夠即時適應患者的生理功能。與傳統的固定輸出刺激器不同，這些創新設備採用先進的感測技術來檢測誘發複合動作電位（ECAP），從而能夠根據患者的脊髓活動和身體運動自動調節刺激強度。這種功能確保了最佳的治療效果，同時避免了咳嗽或彎腰等日常動作常常導致的過度刺激。Medtronic於2025年3月推出的「Inceptiv」閉合迴路可充電脊髓刺激設備便是這項重大進步的體現。此刺激器每秒可偵測50次生物訊號，為慢性疼痛患者提供持續穩定的治療。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球神經痛治療市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 治療方法（藥物治療、手術）
  • 適應症（糖尿病神經病變、肋間神經痛、枕神經痛、周邊神經痛、帶狀帶狀皰疹後遺症神經痛、三叉神經痛）
  • 銷售管道細分（醫院藥局、網路藥局、零售藥局）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美神經痛治療市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲神經痛治療市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區神經痛治療市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東與非洲神經痛治療市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美神經痛治療市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球神經痛治療市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• GSK PLC
• Pfizer Inc
• Novartis AG
• Biogen Inc
• Cadila Pharmaceuticals Ltd
• Lundbeck Pharmaceuticals Ltd
• Zydus Group
• Eli Lily and Company
• Allergan Inc.
• Baxter International Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Neuralgia Treatment Market is projected to expand significantly, growing from USD 1.34 billion in 2025 to USD 2.23 billion by 2031, at a Compound Annual Growth Rate (CAGR) of 8.86%. This market includes various pharmacological and interventional therapies aimed at managing neuropathic pain, a chronic condition characterized by nerve damage resulting in sharp, shooting, or burning sensations. The primary forces propelling this market's growth are the rapidly increasing global elderly population, who are particularly vulnerable to conditions like postherpetic neuralgia, and the rising incidence of chronic metabolic disorders such as diabetes, which frequently lead to peripheral neuropathy.

Despite this growth, market expansion faces significant hurdles, notably adverse drug effects and complex diagnostic procedures, which often lead to patient non-compliance or untreated cases. A major barrier to effective care delivery and market penetration is the high rate of underdiagnosis. For instance, the American Diabetes Association indicated that in 2025, distal symmetric polyneuropathy might affect at least 10% to 15% of newly diagnosed type 2 diabetes patients. This highlights the substantial number of patients needing early neuropathic management who remain undiagnosed, thereby limiting the accessible market for existing treatments.

Market Driver

The increasing prevalence of diabetes and its associated diabetic neuropathy serves as a fundamental catalyst for the Global Neuralgia Treatment Market. Chronic high blood sugar levels systematically damage peripheral nerves, creating a large patient pool suffering from painful diabetic neuropathy (PDN) who require ongoing analgesic or anticonvulsant therapy. This expanding demographic demands a continuous rise in the development and prescription of solutions for neuropathic pain management. According to the International Diabetes Federation's December 2025 'IDF Diabetes Atlas 11th Edition', approximately 589 million adults globally were living with diabetes in 2024, ensuring that diabetic neuropathy remains a dominant clinical indication driving market demand, as a significant portion will eventually require intervention for nerve damage.

Simultaneously, continuous advancements in both pharmacological and surgical pain management interventions are aggressively broadening the market's scope. Manufacturers are increasingly prioritizing the creation of non-opioid pharmaceuticals and sophisticated neuromodulation devices to overcome the limitations of traditional treatments. This strategic shift is marked by substantial investments and key regulatory milestones that enhance both treatment efficacy and patient safety, as evidenced by Boston Scientific's October 2025 acquisition of Nalu Medical for about $533 million to integrate advanced peripheral nerve stimulation technologies. Furthermore, regulatory approvals for next-generation systems, like the U.S. FDA's 2025 approval for Saluda Medical's EVA programming platform to optimize spinal cord stimulation outcomes, are accelerating their adoption.

Market Challenge

Diagnostic complexities present a significant obstacle to the expansion of the global neuralgia treatment market. Neuropathic pain is often subjective and challenging to identify using standard clinical tests, especially in its early stages. Because these sensations can resemble those of other medical conditions, healthcare providers frequently struggle to accurately pinpoint the specific nerve damage, often resulting in delayed or missed diagnoses. When patients do not receive a definitive diagnosis, they cannot be prescribed the necessary pharmacological or interventional therapies, effectively preventing their entry into the consumer base for these treatments.

This high rate of underdiagnosis directly limits the total addressable market size. Without a confirmed diagnosis, patients do not generate demand for prescription analgesics or neurostimulation devices, creating a substantial gap between the actual disease prevalence and treatment revenue. The Foundation for Peripheral Neuropathy estimated that in 2025, around 30 million people in the United States suffered from some form of peripheral neuropathy, yet a considerable number remained untreated due to these diagnostic challenges. This disparity underscores a substantial amount of potential market value that remains inaccessible due to current clinical limitations.

Market Trends

The development of selective voltage-gated sodium channel blockers signifies a transformative change in pharmacological interventions, shifting from broad-spectrum analgesics to precisely targeting peripheral pain signals. This trend focuses on inhibiting specific ion channels, such as NaV1.8, which are highly expressed in nociceptors and crucial for transmitting neuropathic pain, crucially avoiding the central nervous system side effects associated with opioids. The validation of this mechanism has rapidly accelerated, establishing a new class of therapeutics that directly addresses the physiological origin of neuralgia, exemplified by Vertex Pharmaceuticals' January 2025 announcement of U.S. FDA approval for suzetrigine, a highly selective NaV1.8 pain signal inhibitor, marking the first new medicine class for acute pain in over two decades and advancing its Phase 3 development in diabetic peripheral neuropathy.

Concurrently, advancements in next-generation neuromodulation devices are redefining the interventional landscape through the deployment of closed-loop systems that adapt to patient physiology in real-time. Unlike traditional fixed-output stimulators, these innovative devices use sophisticated sensing technology to detect Evoked Compound Action Potentials (ECAPs), enabling the system to automatically adjust stimulation levels based on the patient's spinal cord activity and body movements. This capability ensures optimal therapeutic efficacy while preventing overstimulation often triggered by daily activities like coughing or bending, a pivotal expansion demonstrated by Medtronic's March 2025 announcement of the availability of its Inceptiv closed-loop rechargeable spinal cord stimulator, which senses biological signals 50 times per second to deliver consistent therapy for chronic pain patients.

Key Market Players

• GSK PLC
• Pfizer Inc
• Novartis AG
• Biogen Inc
• Cadila Pharmaceuticals Ltd
• Lundbeck Pharmaceuticals Ltd
• Zydus Group
• Eli Lily and Company
• Allergan Inc.
• Baxter International Inc.

Report Scope

In this report, the Global Neuralgia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Neuralgia Treatment Market, By Treatment

• Drug-Based
• Surgery

Neuralgia Treatment Market, By Indication

• Diabetic Neuropathy
• Intercostal Neuralgia
• Occipital Neuralgia
• Peripheral Neuralgia
• Postherpetic Neuralgia
• Trigeminal Neuralgia

Neuralgia Treatment Market, By Distribution Channel

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

Neuralgia Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Neuralgia Treatment Market.

Available Customizations:

Global Neuralgia Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Neuralgia Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment (Drug-Based, Surgery)
  • 5.2.2. By Indication (Diabetic Neuropathy, Intercostal Neuralgia, Occipital Neuralgia, Peripheral Neuralgia, Postherpetic Neuralgia, Trigeminal Neuralgia)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Neuralgia Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment
  • 6.2.2. By Indication
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Neuralgia Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Neuralgia Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Neuralgia Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By Distribution Channel

7. Europe Neuralgia Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment
  • 7.2.2. By Indication
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Neuralgia Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Neuralgia Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Neuralgia Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Neuralgia Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Neuralgia Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Neuralgia Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment
  • 8.2.2. By Indication
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Neuralgia Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Neuralgia Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Neuralgia Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Neuralgia Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment
      • 8.3.4.2.2. By Indication
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Neuralgia Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment
      • 8.3.5.2.2. By Indication
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Neuralgia Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment
  • 9.2.2. By Indication
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Neuralgia Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Neuralgia Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Neuralgia Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By Distribution Channel

10. South America Neuralgia Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment
  • 10.2.2. By Indication
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Neuralgia Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Neuralgia Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Neuralgia Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Neuralgia Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. GSK PLC
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Pfizer Inc
• 15.3. Novartis AG
• 15.4. Biogen Inc
• 15.5. Cadila Pharmaceuticals Ltd
• 15.6. Lundbeck Pharmaceuticals Ltd
• 15.7. Zydus Group
• 15.8. Eli Lily and Company
• 15.9. Allergan Inc.
• 15.10. Baxter International Inc.

16. Strategic Recommendations

17. About Us & Disclaimer